Skip to search formSkip to main contentSkip to account menu

briakinumab

Known as: Immunoglobulin G1, Anti-(Human Interleukin-12 Subunit Beta (IL-12 Subunit P40, CLMF P40 or NKSF2)); Human Monoclonal Gamma-1 Heavy Chain (218-216')-Disulfide with Human Monoclonal Gamma Light Chain, Dimer (224-224'':227-227'')-Bisdisulfide 
A human monoclonal antibody directed against the human interleukins 12 (IL-12) and 23 (IL-23), with immunomodulating activity. Briakinumab binds to… 
National Institutes of Health

Related topics

Related topics

4 relations
ABT-874 antibody, humanAvakineantigen binding

Broader (1)

Monoclonal Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2018
Highly Cited
2018
Structural Activation of Pro‐inflammatory Human Cytokine IL‐23 by Cognate IL‐23 Receptor Enables Recruitment of the Shared Receptor IL‐12R&bgr;1
Highly Cited
2015
Highly Cited
2015
Briakinumab for Treatment of Crohn's Disease: Results of a Randomized Trial
Background:This study assessed the efficacy and safety of briakinumab, a human anti-IL-12/23p40 monoclonal antibody, compared… 
Highly Cited
2013
Highly Cited
2013
Re‐evaluation of the risk for major adverse cardiovascular events in patients treated with anti‐IL‐12/23 biological agents for chronic plaque psoriasis: a meta‐analysis of randomized controlled…
Objective  To detect a detrimental or beneficial effect of anti‐IL‐12/23 biological agents (ustekinumab and briakinumab) for the… 
Highly Cited
2012
Highly Cited
2012
A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis.
A previous phase II trial demonstrated that the fully human anti-IL-12/23 mAb briakinumab was efficacious in moderate-to-severe… 
2012
2012
Association of ustekinumab and briakinumab with major adverse cardiovascular events
Safety concerns have been raised regarding possible association of major adverse cardiovascular events (MACEs) with use of anti… 
Highly Cited
2012
Highly Cited
2012
Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open‐label extension trial of the interleukin‐12/23 monoclonal antibody…
Background  Anti‐interleukin‐12/23 treatment (anti‐IL‐12/23) has recently demonstrated significant efficacy for moderate to… 
2012
2012
Riesgo cardiovascular y psoriasis: papel de la terapia biológica
Highly Cited
2011
Highly Cited
2011
Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic…
Background  The tumour necrosis factor‐α antagonist etanercept and the interleukin (IL)‐12/23p40 antagonist ustekinumab have been… 
Review
2010
Review
2010
Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents
Psoriasis is a chronic inflammatory disease affecting 1–3% of the general population. Among psoriatic patients, 5–40% are… 
Review
2009
Review
2009
Briakinumab
Background: Psoriasis is a chronic, autoimmune, T-cell mediated, inflammatory disease. An improved understanding of the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)